Acyclovir resistance in herpes simplex virus type I encephalitis: a case report

M. Bergmann 1 · R. Beer 1 · M. Kofer 1 · R. Helbok 1 · B. Pfausler 1 · E. Schmutzhard 1

Abstract Acyclovir resistance is rarely seen in herpes simplex virus (HSV) type I encephalitis. Prevalence rates vary between 0.5 % in immunocompetent patients (Christophers et al. 1998; Fife et al. 1994) and 3.5–10 % in immunocompromised patients (Stranska et al. 2005). We report a 45-year-old, immunocompetent (negative HIV antigen/antibody testing), female patient, without previous illness who developed—after a febrile prodromal stage—aphasia and psychomotor slowing. Cerebral magnetic resonance imaging (cMRI) showed right temporal and insular T2-hyperintense lesions spreading to the contralateral temporal lobe. Cerebrospinal fluid (CSF) analysis yielded lymphocytic pleocytosis and elevated protein level. Polymerase chain reaction testing for HSV type I showed a positive result in repeat lumbar puncture. HSV type I encephalitis was diagnosed and intravenous acyclovir treatment was initiated (750 mg t.i.d.). Acyclovir treatment was intensified to 1000 mg t.i.d., due to clinical deterioration, ongoing pleocytosis and progression on cMRI 5 days after initiation of antiviral therapy. In parallel, acyclovir resistance testing showed mutation of thymidine kinase gene at position A156V prompting foscarnet therapy (60 mg t.i.d.). Patient’s condition improved dramatically over 2 weeks. Acyclovir resistance is rare but should be considered in case of clinical worsening of patient’s condition. To our knowledge, this is the first report of acyclovir resistance in HSV type I encephalitis of an immunocompetent and previously healthy patient in Austria.

Keywords Acyclovir resistance · Herpes simplex virus type I · Encephalitis · Foscarnet

Introduction

Clinically suspected acyclovir resistance of herpes simplex virus (HSV) type I was first described in 1982 (Burns et al. 1982; Crumpacker et al. 1982; Sibrack et al. 1982) with reported prevalence rates of 0.5 % in immunocompetent patients (Christophers et al. 1998; Fife et al. 1994) and 3.5–10 % in immunocompromised patients (Stranska et al. 2005). Even higher prevalence rates (25 %) of acyclovir resistance have been published in bone marrow or allogenic hematopoietic stem cell transplant recipients (Danve-Szatanek et al. 2004; Morfin et al. 2004). Of note, acyclovir resistance in HSV type I encephalitis is rare (Gateley et al. 1990; Schulte et al. 2010).

Report of a case

A 45-year-old woman suffering from right frontal headache, fever, diarrhea, and vomiting, without previous illness, was admitted to a district hospital. She was evaluated for systemic viral disease with negative testing for putative pathogens including human immunodeficiency virus (HIV). White blood cell classification revealed left shift with a rise of neutrophils (neutrophils 8.3 billion cells/L (G/L), total leucocytes 10 G/L, lymphocytes 1.3 G/L, monocytes 0.38 G/L, eosinophils 0 G/L, basophils 0 G/L). Blood immunoglobulin levels were normal. Three days later, she developed psychomotor slowing and aphasia and, finally, became stuporous, but had no obvious neck stiffness. Cerebrospinal fluid (CSF) examination revealed lymphocytic pleocytosis (271 cells/μL; reference <4 cells/μL), mild elevated protein (82 mg/dL; normal range...
<50 mg/dL), but normal glucose concentration. Cerebral magnetic resonance imaging (cMRI) showed T2-hyperintense lesions, mainly involving the right temporal lobe and the insula, as well as the frontal and contralateral temporal regions (Fig. 1). On the following day, a negative PCR testing for HSV type I in the previously drawn CSF sample was reported. However, based upon the patient’s clinical presentation, CSF, and cMRI findings, HSV type I encephalitis was still suspected and intravenous acyclovir (750 mg t.i.d.) had been instituted immediately after the diagnostic procedures. Despite prompt initiation of antiviral therapy, the patient developed repetitive generalized tonic-clonic seizures and respiratory insufficiency requiring mechanical ventilation. Consequently, the patient was transferred to our neurological intensive care unit (ICU). Repeat cMRI 5 days after initiation of acyclovir treatment showed progressing T2-hyperintense lesions (Fig. 2). Further, repeat CSF examination yielded ongoing lymphocytic pleocytosis (243 cells/μL) and this time positive PCR result for HSV type I. To overcome potential inadequate penetration of acyclovir into the intrathecal compartment, the dose of acyclovir was increased to 1000 mg t.i.d. In addition, to rule out suspected resistance to acyclovir, genotype sequencing of thymidine kinase and DNA polymerase genes was performed. Molecular biology testing confirmed mutation of thymidine kinase gene at position A156V. Immediately after positive resistance testing, foscarnet was added at a dose of 60 mg t.i.d. The combination of increased acyclovir dose and the initiation of foscarnet led to a marked improvement of the patient’s condition. The third lumbar puncture performed at day 24 after hospitalization revealed a reduction of CSF pleocytosis to 18 cells/μL and HSV type I DNA was no longer detectable in the CSF.

The patient was then weaned off the ventilator and extubated. At transferal to a specialized neurological rehabilitation facility 1 month after hospital admission the patient still showed residual aphasia, left-sided hemiparesis, and cognitive dysfunction. She left rehabilitation center with modified Rankin scale of 3 (moderate disability).

Discussion

The patient suffered from HSV type I encephalitis and was initially treated with an intravenous acyclovir dose of 750 mg t.i.d. Time from onset of symptoms to treatment was approximately 72 h. Clinical and neuroimaging deterioration together with the development of intracranial hypertension prompted further investigations, particularly for potential presence of acyclovir resistance—even in the case of an immunocompetent patient, however, no further investigation with respect to primary immunodeficiency (Joshi et al. 2009) was carried out. We were able to confirm a mutation (A156V) of the viral enzyme thymidine kinase which converts the prodrug acyclovir to acyclovir monophosphate. A156V mutation is a well-known cause of HSV type I drug resistance.

Acyclovir is the first-line treatment for HSV infections and requires activation via phosphorylation to the triphosphate form. Initially, phosphorylation takes place through thymidine kinase encoded by the human herpesvirus 1 UL23 gene. Further phosphorylation steps occur through cellular thymidylate kinases. Activated acyclovir triphosphate is a competitive inhibitor of the viral DNA polymerase and results in chain termination. Long-term prophylaxis with acyclovir may lead to drug resistance, especially in immunocompromised patients (Andrei and Snoeck 2013). The HSV may become resistant to acyclovir via mutation of the viral
thymidine-kinase gene, mediating approximately 95 % of cases of acyclovir resistance, or via mutation of the DNA polymerase gene. Resistance to acyclovir can be established by clinical observation, phenotyping (testing the susceptibility of a viral isolate to different drug doses), or genotyping by the identification of specific mutations linked with drug resistance (Andrei and Snoeck 2013).

Foscarnet is a direct inhibitor of the virus DNA polymerases and an alternative drug for the treatment of HSV resistant patients (Piret and Boivin 2011; Safrin et al. 1991; Schulte et al. 2010). Alternative therapeutic approaches have been introduced recently, including viral polymerase inhibition by brincidofovir (CMX001), valomaciclovir, and n-methanocarbathymidine. Another option is the inhibition of the helicase primase complex with pritelivir (AIC316) or amenamevir (ASP2151) (Scott and Prichard 2014). Finally, we do not yet know whether increasing the dose of acyclovir or the initiation of foscarnet led to an improvement of our patient’s medical condition.

Conclusion

Acyclovir resistance in HSV type I encephalitis is rare in immunocompetent patients (Gateley et al. 1990; Schulte et al. 2010) but should be considered in cases of clinical deterioration despite antiviral therapy and persistent virus load in the CSF. Here, we report the first case of an immunocompetent patient with acyclovir resistant HSV type I encephalitis in Austria. Genotype sequencing reliably reveals mutations of thymidine kinase as a cause of acyclovir resistance. In our case, increasing the dose of acyclovir during the assessment of resistance and the timely initiation of foscarnet proved life-saving; however, the delay of the appropriate therapy certainly has contributed to medium-term morbidity.

Acknowledgments

Open access funding provided by University of Innsbruck and Medical University of Innsbruck. We thank Dr. Karin Pollak from Medical University Vienna, Department of Virology, for providing genotype sequencing and PD Dr. A. Grams from Medical University Innsbruck, Department of Neuroradiology, for providing cMRI.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Open Access

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Andrei G, Snoeck R (2013) Herpes simplex virus drug-resistance: new mutations and insights. Curr Opin Infect Dis 26:551–560

Burns WH, Saral R, Santos GW, Laskin OL, Lietman PS, McLaren C, Barry DW (1982) Isolation and characterisation of resistant Herpes simplex virus after acyclovir therapy. Lancet 1:421–423

Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, Darby G (1998) Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 42:868–872

Crumpacker CS, Schnipper LE, Marlowe SI, Kowalsky PN, Hershey BJ, Levin MJ (1982) Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 306:343–346

Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, Billaudel S, Chanzy B, Coste-Burel M, Finkieltsstein L, Fleury H, Hadou T, Henquell C, Lafuette H, Lafon ME, Le FA, Legrand MC, Maille L, Mengelle C, Morand P, Morinet F, Nicand E, Omar S, Picard B, Pozzetto B, Puel J, Raoul D, Scieux C, Segondy M, Seigneurin JM, Teysouur S, Zandotti C (2004) Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 42:242–249

Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS (1994) Recurrence and resistance patterns of herpes simplex virus following cessation of > or =6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 169:1338–1341

Gateley A, Gander RM, Johnson PC, Kit S, Otsuka H, Kohl S (1990) Herpes simplex virus type 2 meningoecephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 161:711–715

Joshi AY, Iyer VN, Hagan JB, St Sauver JL, Boyce TG (2009) Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc 84:16–22

Morfin F, Bilger K, Boucher A, Thiebaut A, Najjoullah F, Bleyzac N, Raus N, Bosshard S, Aymard M, Michallet M, Thouvenot D (2004) HSV excretion after bone marrow transplantation: a 4-year survey. J Clin Virol 30:341–345

Piret J, Boivin G (2011) Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 55:459–472

Safrin S, Crumpacker C, Chatis P (1991) A controlled trial comparing foscarnet with vidarabine for acyclovir resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 325:551–555

Schulte EC, Sauerbrei A, Hoffmann D, Zimmer C, Hemmer B, Muhlau M (2010) Acyclovir resistance in herpes simplex encephalitis. Ann Neurol 67:830–833

Scott HJ, Prichard MN (2014) Current and future therapies for therapies for herpes simplex virus infections: mechanism of action and drug resistance. Curr Opinion Virol 5:54–61

Sibrack CD, Gutman LT, Wilfert CM, McLaren C, St Clair MH, Keller PM, Barry DW (1982) Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 146:673–682

Stranska R, Schaumman R, Nienhuis E, Goedegebureu JW, Polman M, Weel JF, Wertheim-Van Dillen PM, Berkhout RJ, van Loon AM (2005) Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 32:7–18